Business Context and Reporting Period
Company: pSivida Corp. (Note: Input metadata referenced "Eyepoint, Inc.", but the filing text identifies the registrant as pSivida Corp.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2009
Business Overview: pSivida develops sustained-release drug delivery products. Key technologies include Durasert (licensed to Alimera for Iluvien and Bausch & Lomb for Retisert/Vitrasert) and BioSilicon (lead candidate BrachySil for cancer treatment). The company relies on collaboration agreements with Pfizer and Alimera for funding and revenue.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2009 | Six Months Ended Dec 31, 2009 |
|---|---|---|
| Total Revenues | $3.43 million | $6.82 million |
| Net Loss | $(0.02) million | $(1.62) million |
| Operating Loss | $(0.11) million | $(0.22) million |
| Cash and Cash Equivalents | $5.13 million (Ending Balance) | $5.13 million (Ending Balance) |
| Net Cash Used in Operating Activities | N/A | $(2.25) million |
| Total Assets | $32.63 million | $32.63 million |
| Total Liabilities | $10.15 million | $10.15 million |
| Stockholders' Equity | $22.48 million | $22.48 million |
Debt and Liquidity: The company has no borrowings or line of credit facilities. Liquidity is supported by cash reserves and expected payments from collaboration partners (Pfizer and Alimera). Management believes current cash is sufficient to fund operations through at least December 31, 2010.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 16% ($0.46 million) for the three months and 18% ($1.04 million) for the six months ended December 31, 2009, compared to the prior year periods. This was driven primarily by the Alimera collaboration agreement.
- Expense Reduction: Total operating expenses decreased 19% ($0.85 million) for the quarter and 27% ($2.54 million) for the six months.
- R&D: Decreased due to the completion of BrachySil Phase II trials and reduced UK-based costs.
- G&A: Decreased significantly due to the absence of a $1.3 million provision for losses on a note receivable recorded in the prior year and reduced professional fees following reincorporation in the U.S.
- Derivative Liability Volatility: The change in fair value of derivative liabilities (A$-denominated warrants) resulted in a non-cash expense of $1.44 million for the six months ended Dec 31, 2009, compared to income of $1.56 million in the prior year period. This swing was driven by fluctuations in the company's share price.
- Net Loss: Net loss improved significantly for the quarter (down 97% to $0.02 million) but increased for the six-month period (up 20% to $1.62 million) primarily due to the derivative liability expense.
Outlook, Risks, and Management Commentary
- Product Pipeline:
- Iluvien (Alimera): Alimera plans to file a New Drug Application (NDA) with the FDA in Q2 2010, requesting Priority Review. Approval could lead to commercialization in Q1 2011. A $25 million milestone payment is due upon FDA approval.
- BrachySil (BioSilicon): Completed dose-ranging clinical trials for pancreatic cancer in October 2009. The company is seeking a development partner for a pivotal Phase III trial.
- Liquidity Outlook: Management expects to fund operations through at least December 31, 2010, contingent on continued funding from Pfizer and Alimera. Contingency plans include reducing spending on non-critical activities if payments fall short.
- Key Risks:
- Failure to obtain FDA approval for Iluvien or BrachySil.
- Dependence on collaboration partners (Alimera, Pfizer) for funding and milestone payments.
- Volatility in the fair value of derivative liabilities due to share price fluctuations.
- Potential need for additional capital if collaborations do not generate sufficient cash flow.
- Unusual Items: The financial results are significantly impacted by non-cash charges related to the revaluation of derivative liabilities and amortization of intangible assets ($1.68 million for the six months).
Investor Verification Checklist
- Alimera NDA Timeline: Verify the status of the NDA filing for Iluvien and the likelihood of FDA Priority Review as projected for Q2 2010.
- Derivative Liability Exposure: Assess the sensitivity of future earnings to share price volatility, given the $2.4 million derivative liability balance.
- Cash Burn Rate: Confirm the company's ability to maintain operations through December 2010 without additional equity financing, specifically monitoring the receipt of quarterly payments from Pfizer and Alimera.
- Retisert Royalties: Note that royalty income from Retisert is currently deferred; verify the timeline for when Bausch & Lomb's retention of royalties will be exhausted.
- Intangible Asset Amortization: Review the $3.3 million annual amortization expense associated with the $26.4 million net book value of intangible assets.